Modification of PLAC8 by UFM1 affects tumorous proliferation and immune response by impacting PD-L1 levels in triple-negative breast cancer

Background Triple-negative breast cancer is characterized by a poor prognosis and lack of targeted treatments, and thus, new targeting markers and therapeutic strategies are urgently needed. We previously indicated that PLAC8 promotes tumorigenesis and exerts multidrug resistance in breast cancer. Therefore, we aimed to characterize the PLAC8-regulated network in triple-negative breast cancer. Methods We measured the levels of PLAC8 in breast cancer cell lines and found that PLAC8 is post-translationally modified by ubiquitin-fold modifier 1 (UFM1). Then, we revealed a new regulatory system of PD-L1 by PLAC8 in triple-negative breast cancer. We also tested the molecular functions of PLAC8 in triple-negative breast cancer cell lines and measured the expression of PLAC8 and PD-L1 in breast cancer tissues. Results PLAC8 was generally highly expressed in triple-negative breast cancer and could be modified by UFM1, which maintains PLAC8 protein stability. Moreover, PLAC8 could promote cancer cell proliferation and affect the immune response by regulating the level of PD-L1 ubiquitination. Additionally, among patients with breast cancer, the expression of PLAC8 was higher in triple-negative breast cancer than in non-triple-negative breast cancer and positively correlated with the level of PD-L1. Conclusions Our current study discoveries a new PLAC8-regulated network in triple-negative breast cancer and provides corresponding guidance for the clinical diagnosis and immunotherapy of triple-negative breast cancer.

[1]  Yifan Cheng,et al.  Multifaced roles of PLAC8 in cancer , 2021, Biomarker research.

[2]  Y. Wang,et al.  Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Wen-xian Hu,et al.  PLAC8 promotes adriamycin resistance via blocking autophagy in breast cancer , 2021, Journal of cellular and molecular medicine.

[4]  Ji Wang,et al.  Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer , 2021, Journal of Experimental & Clinical Cancer Research.

[5]  Tingjun Hou,et al.  ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation , 2021, Nature Communications.

[6]  Yin-hua Yu,et al.  PLAC8 promotes the autophagic activity and improves the growth priority of human trophoblast cells , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  Rong-yue Teng,et al.  Regulation of tamoxifen sensitivity by the PLAC8/MAPK pathway axis is antagonized by curcumin-induced protein stability change , 2021, Journal of Molecular Medicine.

[8]  Sarah A. Boswell,et al.  Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer , 2020, Nature Cancer.

[9]  Yinlu Ding,et al.  The ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression , 2020, Oncogene.

[10]  D. Guan,et al.  UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination , 2020, Nature Cell Biology.

[11]  R. Deng,et al.  Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation , 2020, Nature Communications.

[12]  S. Fan,et al.  The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells , 2020, Cell Communication and Signaling.

[13]  Thomas O. McDonald,et al.  Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer , 2020, Nature Communications.

[14]  J. Tobias,et al.  Loss of ELF5–FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling , 2020, Nature Cell Biology.

[15]  R. Jiang,et al.  The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer , 2020, Molecular Cancer.

[16]  T. Kang,et al.  NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer , 2020, Nature Communications.

[17]  Kaiyuan Deng,et al.  CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism , 2020, Signal Transduction and Targeted Therapy.

[18]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[19]  Ahmedin Jemal,et al.  Breast cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[20]  S. Póliska,et al.  Coagulation FXIII-A Protein Expression Defines Three Novel Sub-populations in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia Characterized by Distinct Gene Expression Signatures , 2019, Front. Oncol..

[21]  Yongxia Chen,et al.  PLCA8 suppresses breast cancer apoptosis by activating the PI3k/AKT/NF‐κB pathway , 2019, Journal of cellular and molecular medicine.

[22]  D. Mukhopadhyay,et al.  BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts , 2019, Oncogene.

[23]  Liewei Wang,et al.  UFL1 promotes histone H4 ufmylation and ATM activation , 2019, Nature Communications.

[24]  S. O'Reilly,et al.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.

[25]  Wei-Guo Zhu,et al.  MRE11 UFMylation promotes ATM activation , 2019, Nucleic acids research.

[26]  M. Iorio,et al.  WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer , 2019, Oncogene.

[27]  M. Hung,et al.  Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. , 2018, Cancer research.

[28]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[29]  W. Symmans,et al.  Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[30]  E. Shin,et al.  YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma , 2018, Cancer Immunology Research.

[31]  Baoli Heng,et al.  Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma , 2017, International Urology and Nephrology.

[32]  G. Hortobagyi,et al.  Deubiquitination and Stabilization of PD-L1 by CSN5. , 2016, Cancer cell.

[33]  Jun Yao,et al.  Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity , 2016, Nature Communications.

[34]  Jong Ho Park,et al.  Ubiquitin-Fold Modifier 1 Acts as a Positive Regulator of Breast Cancer , 2015, Front. Endocrinol..

[35]  Ivan Dikic,et al.  Ubiquitination in disease pathogenesis and treatment , 2014, Nature Medicine.

[36]  D. Noh,et al.  Modification of ASC1 by UFM1 is crucial for ERα transactivation and breast cancer development. , 2014, Molecular cell.

[37]  M. Washington,et al.  Excess PLAC8 promotes an unconventional ERK2-dependent EMT in colon cancer. , 2014, The Journal of clinical investigation.

[38]  Keiji Tanaka,et al.  A novel protein‐conjugating system for Ufm1, a ubiquitin‐fold modifier , 2004, The EMBO journal.

[39]  Mamoru Fukuda,et al.  Ubiquitin and breast cancer , 2004, Oncogene.